Executive Summary
Curio Bioscience petitions the PTAB to invalidate claims of U.S. Patent 11,549,138 covering spatially encoded biological assays, arguing obviousness over Cantor and Armani and anticipation by Frisen, and asserting lack of written description support.
Related Cases
Texas Instruments IncorporatedvsParkerVision, Inc.
Texas Instruments (Petitioner) successfully secured institution of its Inter Partes Review petition against ParkerVision's patent (9118528). The Board found a reasonable likelihood of obviousness over combinations including Tayloe, TI Datasheet, and Macnally.
Sun Pharmaceutical Industries, Inc.vsBiofrontera Inc.
Sun Pharmaceutical has filed a post‑grant review petition seeking cancellation of all 17 claims of Biofrontera’s nanoemulsion patent, alleging anticipation and obviousness over the Uhlmann and Palazzolo prior‑art references.
Snap, Inc.vsNokia Technologies Oy
The USPTO Board denied institution for the IPR challenge brought by Snap, Inc. against Nokia's patent 8175148.
Microsoft CorporationvsDialect, LLC
A 2024 study of PTAB final written decisions from 2021 shows that patents invalidated in IPRs often have extensive prior‑art citations and that most unpatentability grounds depend on new prior art introduced during the proceeding, with expert testimony frequently influencing outcomes.
TESLA, INC.vsAutonomous Devices, LLC
Tesla (Petitioner) challenged Autonomous Devices' patent in an IPR proceeding, arguing that the claims are anticipated or obvious over prior art references like Buibas and Grotmol. The Board found factors favoring institution, meaning the case will proceed to the merits phase.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.